Wall Street analysts forecast that NanoString Technologies Inc (NASDAQ:NSTG) will post earnings of ($0.65) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for NanoString Technologies’ earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.63). NanoString Technologies posted earnings of ($0.75) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 13.3%. The firm is expected to announce its next quarterly earnings results after the market closes on Thursday, May 9th.

On average, analysts expect that NanoString Technologies will report full-year earnings of ($2.36) per share for the current fiscal year, with EPS estimates ranging from ($2.42) to ($2.24). For the next financial year, analysts forecast that the firm will post earnings of ($2.15) per share, with EPS estimates ranging from ($2.78) to ($1.78). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for NanoString Technologies.

NanoString Technologies (NASDAQ:NSTG) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.18). The company had revenue of $30.03 million during the quarter. NanoString Technologies had a negative net margin of 72.52% and a negative return on equity of 252.59%.

A number of brokerages have recently issued reports on NSTG. Zacks Investment Research downgraded shares of NanoString Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $35.00 price target on shares of NanoString Technologies in a report on Friday, March 8th. BidaskClub downgraded shares of NanoString Technologies from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 14th. Finally, ValuEngine upgraded shares of NanoString Technologies from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 2nd. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $22.80.

Shares of NSTG traded down $0.13 during trading hours on Friday, reaching $23.71. The company had a trading volume of 337,481 shares, compared to its average volume of 571,314. The company has a quick ratio of 2.75, a current ratio of 3.05 and a debt-to-equity ratio of 1.58. The company has a market capitalization of $737.03 million, a PE ratio of -8.53 and a beta of 1.30. NanoString Technologies has a 12-month low of $8.97 and a 12-month high of $31.14.

In other NanoString Technologies news, SVP Mary Tedd Allen sold 2,941 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $25.91, for a total transaction of $76,201.31. Following the completion of the transaction, the senior vice president now directly owns 24,996 shares in the company, valued at approximately $647,646.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider R Bradley Gray sold 20,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $22.28, for a total transaction of $445,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,088,141 shares of company stock valued at $43,896,351 over the last 90 days. 20.90% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in NanoString Technologies by 19.4% during the 3rd quarter. BlackRock Inc. now owns 2,211,521 shares of the biotechnology company’s stock valued at $39,432,000 after acquiring an additional 358,991 shares in the last quarter. Morgan Stanley increased its holdings in NanoString Technologies by 16.6% during the 3rd quarter. Morgan Stanley now owns 1,807,118 shares of the biotechnology company’s stock valued at $32,221,000 after acquiring an additional 257,703 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in NanoString Technologies by 22.9% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,232,787 shares of the biotechnology company’s stock valued at $21,980,000 after acquiring an additional 229,486 shares in the last quarter. Vanguard Group Inc increased its holdings in NanoString Technologies by 11.2% during the 3rd quarter. Vanguard Group Inc now owns 1,224,123 shares of the biotechnology company’s stock valued at $21,827,000 after acquiring an additional 122,908 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in NanoString Technologies by 11.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,224,123 shares of the biotechnology company’s stock valued at $21,827,000 after acquiring an additional 122,908 shares in the last quarter. Hedge funds and other institutional investors own 87.94% of the company’s stock.

About NanoString Technologies

NanoString Technologies, Inc engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway.

Featured Article: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on NanoString Technologies (NSTG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.